FDA grants fast track designation to Calibr’s ‘switchable’ CAR-T cell cancer therapy, CLBR001 + SWI019

Scripps Research

1 October 2020 - Phase 1 clinical trial is now enrolling patients with blood cancers.

The U.S. Food and Drug Administration has granted Fast Track designation to a novel “switchable” CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. 

The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia.

Read Scripps Research press release

Michael Wonder

Posted by:

Michael Wonder